Showing 6,841 - 6,860 results of 18,013 for search 'significant ((((((shape decrease) OR (step decrease))) OR (greatest decrease))) OR (a decrease))', query time: 0.88s Refine Results
  1. 6841

    Factors associated with mosquito net integrity. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  2. 6842

    LLINs knockdown performance over time. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  3. 6843

    Factors affecting PBO-LLINs integrity. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  4. 6844

    Net bioefficacy data. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  5. 6845

    House structure and status. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  6. 6846

    LLINs hole positions over time. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  7. 6847
  8. 6848
  9. 6849

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  10. 6850

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  11. 6851

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  12. 6852
  13. 6853
  14. 6854

    Table 3_Ageing, clinical complexity, and exercise therapy: a multidimensional approach.docx by Salvatore Corrao (441339)

    Published 2025
    “…Ageing represents the primary risk factor for chronic degenerative diseases, especially involving cardiovascular, metabolic, respiratory, and osteoarticular systems, determining the decrease in activities and quality of daily life. Regular physical activity can significantly reduce the risk of chronic degenerative diseases, moderate or severe functional limitations, and premature death in older adults. …”
  15. 6855

    Table 1_Ageing, clinical complexity, and exercise therapy: a multidimensional approach.docx by Salvatore Corrao (441339)

    Published 2025
    “…Ageing represents the primary risk factor for chronic degenerative diseases, especially involving cardiovascular, metabolic, respiratory, and osteoarticular systems, determining the decrease in activities and quality of daily life. Regular physical activity can significantly reduce the risk of chronic degenerative diseases, moderate or severe functional limitations, and premature death in older adults. …”
  16. 6856

    Table 2_Ageing, clinical complexity, and exercise therapy: a multidimensional approach.docx by Salvatore Corrao (441339)

    Published 2025
    “…Ageing represents the primary risk factor for chronic degenerative diseases, especially involving cardiovascular, metabolic, respiratory, and osteoarticular systems, determining the decrease in activities and quality of daily life. Regular physical activity can significantly reduce the risk of chronic degenerative diseases, moderate or severe functional limitations, and premature death in older adults. …”
  17. 6857

    Infrared thermal images of typical subjects. by Yongliang Jiang (6200549)

    Published 2025
    “…Regarding the thermal characteristics, compared with the healthy control group, the temperature of the somatic sites of the heart meridian (Shenmen(HT7)/Shaohai(HT3)), as well as Taiyuan (LU9) of the lung meridian, increased significantly (<i><i>P</i></i> < 0.05). With regard to the metabolic features, rSO<sub>2</sub> of the somatic site of the heart meridian (Shaohai (HT3)) in the CSAP group decreased significantly (<i><i>P</i></i> < 0.05) as compared to the healthy control group. …”
  18. 6858

    The CONSORT flowchart of the study. by Yongliang Jiang (6200549)

    Published 2025
    “…Regarding the thermal characteristics, compared with the healthy control group, the temperature of the somatic sites of the heart meridian (Shenmen(HT7)/Shaohai(HT3)), as well as Taiyuan (LU9) of the lung meridian, increased significantly (<i><i>P</i></i> < 0.05). With regard to the metabolic features, rSO<sub>2</sub> of the somatic site of the heart meridian (Shaohai (HT3)) in the CSAP group decreased significantly (<i><i>P</i></i> < 0.05) as compared to the healthy control group. …”
  19. 6859

    Location of 4 somatic measurement sites. by Yongliang Jiang (6200549)

    Published 2025
    “…Regarding the thermal characteristics, compared with the healthy control group, the temperature of the somatic sites of the heart meridian (Shenmen(HT7)/Shaohai(HT3)), as well as Taiyuan (LU9) of the lung meridian, increased significantly (<i><i>P</i></i> < 0.05). With regard to the metabolic features, rSO<sub>2</sub> of the somatic site of the heart meridian (Shaohai (HT3)) in the CSAP group decreased significantly (<i><i>P</i></i> < 0.05) as compared to the healthy control group. …”
  20. 6860

    Minimal data set. by Yongliang Jiang (6200549)

    Published 2025
    “…Regarding the thermal characteristics, compared with the healthy control group, the temperature of the somatic sites of the heart meridian (Shenmen(HT7)/Shaohai(HT3)), as well as Taiyuan (LU9) of the lung meridian, increased significantly (<i><i>P</i></i> < 0.05). With regard to the metabolic features, rSO<sub>2</sub> of the somatic site of the heart meridian (Shaohai (HT3)) in the CSAP group decreased significantly (<i><i>P</i></i> < 0.05) as compared to the healthy control group. …”